MustGrow Biologics, a Canadian-based agricultural biotech company, could make a big leap. This, after reaching an agreement with the German pharmaceutical company Bayer so that it evaluates its biological technologies to determine the efficacy and its commercial potential in key agricultural regions such as Europe, Asia-Pacific, the Middle East and Africa.
Según un comunicado de prensa de MustGrow, la canadiense concedió a Bayer el derecho a utilizar la propiedad intelectual de la empresa con fines de prueba y la opción de adquirir los derechos exclusivos de sus tecnologías para la fumigación del suelo antes de la siembra, las aplicaciones de bioherbicidas y la conservación de las patatas después de la cosecha, incluida la inhibición de la brotación en las regiones de Europa, Asia Pacífico, Medio Oriente y África.
Under the agreement, Bayer will fund and drive all laboratory, field development, regulatory work and market development necessary for commercialization. MustGrow will continue to conduct field testing, R&D and regulatory development simultaneously in other regions, collaborating with numerous consumer food, chemical and agricultural companies.
MustGrow's line of technology focuses on safe, effective and organic plant-based biopesticides that harness the natural defense mechanism of the mustard seed to treat diseases, pests and weeds. The company's technology has demonstrated consistent efficacy in many regions of North and South America, on multiple crops, covering many pests, for several years.
“We are thrilled to accelerate the development and understanding of our technology with Bayer in these important food-producing regions”, says Corey Giasson, CEO of MustGrow. “I am hopeful that we potentially have a sustainable solution for farmers to help with key issues in their production of food.”
